BOTHELL, Wash., July 25 /PRNewswire-FirstCall/ -- Cardiac Science Corporation , a global leader in advanced cardiac monitoring and defibrillation products, announced today that it has received Frost & Sullivan’s award for Global Excellence in ECG Monitoring, which recognizes its superior leadership and innovative vision in the cardiac monitoring marketplace.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGO )
Frost & Sullivan determines the Award recipient based on numerous factors, including the company’s business development, competitive strategy and leadership within the Frost & Sullivan ECG Monitoring Industry Research Group.
Cardiac Science’s leadership in cardiac monitoring is the product of two of its predecessor companies, Quinton Cardiology Systems and Burdick Inc. Quinton acquired Burdick in 2003 and Cardiac Science in September 2005. Today, Cardiac Science is a global leader in the development, manufacture and marketing of non-invasive, diagnostic and therapeutic cardiology devices and services, including industry-leading electrocardiography devices marketed under the Burdick and Quinton brand names.
Burdick and Quinton brand ECGs offer hospitals and physicians a variety of solutions, including traditional and PC-based ECGs, for both acute and ambulatory care settings. The Company’s current product line features innovations that are well known for ensuring timely, high-quality and accurate ECG results critical for patient care, including:
* Leading-edge communications capabilities, including connectivity to leading electronic medical record (EMR) software and systems; * Comprehensive ECG data management, capturing patient reports from stress systems, Holter monitors and ECG devices; * An industry-leading interpretation algorithm that considers five clinically significant criteria.
“Our Burdick and Quinton brand devices have maintained the respect and loyalty of hospital and physician customers for decades,” said John Hinson, Cardiac Science president and CEO. “We believe that this is due to our commitment to providing quality, innovation and superior service to physicians on the front-line of cardiac care, and setting the standard for clinical efficacy and ease-of-use. We are delighted that Frost & Sullivan has chosen to recognize our continued leadership and innovation in this marketplace.”
This is the second time Cardiac Science has been recognized by Frost & Sullivan for its leadership in this market. Frost & Sullivan awarded Quinton Cardiology Systems, one of Cardiac Science’s predecessor companies, its prestigious Growth Strategy Excellence Award in the global market for cardiovascular monitoring devices in March 2004.
For more information on Frost & Sullivan’s Best Practices Awards, go to http://www.awards.frost.com.
About Cardiac Science Corporation
Cardiac Science is truly at the heart of saving lives. The Company develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including AEDs, electrocardiographs, stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, patient monitor - defibrillators and cardiology data management systems. Cardiac Science also sells a variety of related products and consumables, and provides a comprehensive portfolio of training, maintenance and support services. The Company is the successor to various entities that have owned and operated cardiology-related businesses that sold products under the trusted brand names Burdick(R), Powerheart(R), and Quinton(R). Cardiac Science is headquartered in Bothell, WA, and also has operations in Lake Forest, California; Deerfield, Wisconsin; Shanghai, China; Copenhagen, Denmark; and Manchester, United Kingdom.
Forward Looking Statements
This press release contains forward-looking statements. The words “believe,” “expect,” “intend,” anticipate,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward looking statements in this press release include those that infer or imply that our ECG products will be successful in the marketplace resulting in increasing revenues and profits. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in the 10-k filed by Cardiac Science Corporation for the year ended December 31, 2006. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.
Company Contact: Mike Matysik Cardiac Science Corporation Sr. Vice President and CFO 425-402-2009 Investor Contact: EVC Group, Inc. Douglas Sherk/Jenifer Kirtland 415-896-6820 Media Contact: EVC Group, Inc. Jen Saunders 646-201-5431
Photo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comCardiac Science Corporation
CONTACT: Mike Matysik, Sr. Vice President and CFO of Cardiac ScienceCorporation, +1-425-402-2009; or invesors, Douglas Sherk/Jenifer Kirtland,+1-415-896-6820, or media, Jen Saunders, +1-646-201-5431, all of EVC Group,Inc., for Cardiac Science Corporation
Web site: http://www.cardiacscience.com//
